Neurogene (NGNE) Return on Invested Capital (2014)
Neurogene posted quarterly Return on Invested Capital of 0.01% for Q4 2014.
Neurogene (NGNE) has 1 years of Return on Invested Capital data on file, last reported at 0.01% in Q4 2014.
- For the quarter ending Q4 2014, Return on Invested Capital changed N/A year-over-year to 0.01%; the trailing twelve-month figure through Dec 2014 stood at 0.01% (changed N/A YoY), and the FY2014 full-year result was 0.02%, up 1.0% from the prior year.
- Return on Invested Capital for Q4 2014 stood at 0.01%.
- Across five years, Return on Invested Capital topped out at 0.01% in Q4 2014 and bottomed at 0.01% in Q4 2014.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROIC (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -0.01% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 0.00% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -0.01% |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 0.00% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 0.01% |
| 10 | Neurogene | 632.14 Mn | 632.14 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2014 | -0.01% |